Boris Gorelik
Fortuna: - $ al 31/08/2026
Fortuna: - $ al 31/08/2026
Boris Gorelik is currently VP-Business Development & Strategic Programs at Kamada Ltd. since 2022.
Formerly, Mr. Gorelik was Senior Director-Corporate Business Development at Teva Pharmaceutical Industries Ltd. and Chief Financial Officer at Nextgen Biomed Ltd. from 2016 to 2019.
Education includes undergraduate, graduate, and MBA degrees from Tel-Aviv University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
KAMADA LTD -.--% | 07/04/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| KAMADA LTD. | Corporate Officer/Principal | 01/04/2020 |
| Empresas | Cargo | Fin |
|---|---|---|
| NEXTGEN BIOMED LTD | Director Financiero/CFO | 31/07/2019 |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
Tel-Aviv University
Tel-Aviv University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kamada Ltd.
Kamada Ltd. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and manufactures plasma-derived therapeutics products | Health Technology |
Nextgen Biomed Ltd.
Nextgen Biomed Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures skin diseases pharmaceutical products | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.